The American College of Obstetricians and Gynecologists (ACOG) now recommends screening for perinatal depression, stating that “clinicians screen patients at least once during the perinatal period for depression and anxiety symptoms using a standard, [...]
While we have been talking about using brexanolone, marketed by Sage Therapeutics as Zulresso, for the treatment of postpartum depression, an oral version of this novel antidepressant - SAGE 217 or zuranolone - has [...]
Depressive symptoms were assessed in a group of 622 Canadian first-time fathers during their partner’s third trimester using the Edinburgh Postnatal Depression Scale (EPDS). The prevalence of depressive symptoms in fathers was 13.76% at 2 [...]
A mother’s emotional relationship with her baby begins during her pregnancy. After her baby is born, the mother’s feelings about her baby, described as bonding, typically grow and intensify and become the foundation of the [...]
In 2015, we first reported on SAGE-547 (SAGE Therapeutics), a new medication for the treatment of postpartum depression (PPD). SAGE-547, now called brexanolone, is an allosteric modulator of GABAA receptors. Since that time, Sage Therapeutics [...]
In the United States, about one out of every 160 pregnancies ends in stillbirth, defined as a pregnancy loss occurring after 20 weeks' gestation. Perinatal loss is a traumatic event for women and their families. [...]
The American College of Obstetricians and Gynecologists (ACOG) has made a significant change to its recommendations for optimal postpartum care. Previously, ACOG has recommended that women receive a single, comprehensive postpartum visit within the first [...]
Multiple studies have demonstrated the effectiveness of antidepressant medications for the treatment of postpartum depression (PPD). Most of the these studies focused on the impact of these medications on depressive symptoms; however, it is [...]
Because estrogen-containing contraceptives may affect lactation and may increase the risk of thrombosis, progestin-only contraceptives are used in women who are breastfeeding. Depo-Provera (DMPA), which contains medroxyprogesterone, is frequently used during the immediate postpartum period [...]
As we move toward universal screening for perinatal depression, one of our most significant challenges will be to evaluate and deliver care to the women who are identified as being depressed. It is discouraging [...]
